Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Ambrisentan). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
ইঙ্গিত ও ব্যবহার
Ambrisan 10 এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
Adult dose: Treatment usually starts at 5 mg once daily. If this dose is well tolerated, it may be increased to 10 mg once daily. Ambrisentan can be taken with or without food. Pediatric patients: Safety and effectiveness in children have not been established.
পার্শ্বপ্রতিক্রিয়া
Decreases in hemoglobin concentration and hematocrit have been seen with other endothelin receptor antagonists, and this effect was also observed in clinical studies with Ambrisan.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Fluid Retention: Peripheral edema is a recognised class effect of endothelin receptor antagonists, and can also occur as a clinical consequence of PAH itself and of worsening PAH. Pulmonary Veno-occlusive Disease: If a patient develops acute pulmonary edema after starting a vasodilating agent such as Ambrisan, pulmonary veno-occlusive disease should be considered as a possible cause. If this is confirmed, Ambrisan should be discontinued. Haematological Changes: Endothelin receptor antagonists, including Ambrisan, have been associated with decreases in haemoglobin concentration and haematocrit; such decreases were observed in clinical studies with Ambrisan. Hepatic Impairment: Ambrisan is not recommended for patients with moderate or severe hepatic impairment.
নিষেধাজ্ঞা
Ambrisentan can harm an unborn baby if taken during pregnancy, so it must not be used by women who are or could become pregnant. Anyone who takes this medicine while pregnant, or who becomes pregnant while on it, should be made fully aware of the risk this poses to the baby. Before starting Ambrisentan, pregnancy must be ruled out, and effective measures should be taken to avoid pregnancy both during treatment and for one month after stopping it. This medicine is also not suitable for patients with Idiopathic Pulmonary Fibrosis (IPF), including those with IPF accompanied by pulmonary hypertension (WHO Group 3).